NCT04303845终止2 期
Erenumab For Treatment of Hemicrania Continua
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Mayo Clinic
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Headache Days
研究概览
简要总结
This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. The study is also evaluating the safety and tolerability of erenumab in individuals being treated for hemicrania continua.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 66 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Treatment with Erenumab
Experimental
Subjects diagnosed with hemicrania continua will receive single dose of Erenumab
干预措施: Erenumab (Drug)
结局指标
主要结局
Headache Days
时间窗: 4 weeks post erenumab treatment
The total number of days per month (28 days) with headache of any kind/severity
次要结局
- Migraine Days(4 weeks post erenumab treatment)
- Headache Freedom(4 weeks post erenumab treatment)
- Remission Rate(4 weeks post erenumab treatment)
研究者
Rashmi B. Halker Singh MD
Principal Investigator
Mayo Clinic
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic MigraineMigraineNCT04252742Amgen512
撤回
3 期
Investigational Use of Erenumab for the Treatment of Fibromyalgia PainFibromyalgiaNCT06411067United States Naval Medical Center, Portsmouth5
已完成
1 期
Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine PatientsMigraineNCT01723514Amgen48
已完成
1 期
Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine PatientsMigraineNCT01688739Amgen61
已完成
1 期
Ranibizumab in Hemorrhagic Choroidal Neovascularization TrialChoroidal NeovascularizationNCT00363168Johns Hopkins University7